Search

Your search keyword '"Thilo Pluntke"' showing total 2 results
Start Over Author "Thilo Pluntke"
2 results on '"Thilo Pluntke"'

1. Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study

Author

Julian Stumpf, Jörg Schwöbel, Tom Lindner, Leona Anders, Torsten Siepmann, Claudia Karger, Jan Hüther, Heike Martin, Petra Müller, Robert Faulhaber-Walter, Torsten Langer, Holger Schirutschke, Thomas Stehr, Frank Meistring, Annegret Pietzonka, Kirsten Anding-Rost, Katja Escher, Frank Pistrosch, Jens Schewe, Harald Seidel, Kerstin Barnett, Thilo Pluntke, Simon Cerny, Alexander Paliege, Ingolf Bast, Anne Steglich, Florian Gembardt, Friederike Kessel, Hannah Kröger, Patrick Arndt, Jan Sradnick, Kerstin Frank, Anna Klimova, René Mauer, Xina Grählert, Torsten Tonn, and Christian Hugo

Subjects
SARS-CoV-2mRNA vaccination, Antibody fading, Medical personnel, Dialysis patients, Kidney transplant recipients, Public aspects of medicine, RA1-1270
Abstract

Summary: Background: Vulnerable dialysis and kidney transplant patients show impaired seroconversion rates compared to medical personnel eight weeks after SARS-CoV-2mRNA vaccination. Methods: We evaluated six months follow up data in our observational Dia-Vacc study exploring specific cellular (interferon-γ release assay) or/and humoral immune responses after 2x SARS-CoV-2mRNA vaccination in 1205 participants including medical personnel (125 MP), dialysis patients (970 DP) and kidney transplant recipients (110 KTR) with seroconversion (de novo IgA or IgG antibody positivity by ELISA) after eight weeks. Findings: Six months after vaccination, seroconversion remained positive in 98% of MP, but 91%/87% of DP/KTR (p = 0·005), respectively. Receptor binding domain-IgG (RBD-IgG) antibodies were positive in 98% of MP, but only 68%/57% of DP/KTR (p

Published
2022
Full Text
View/download PDF

2. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine

Author

René Mauer, Patrick Arndt, Xina Grählert, Christian Hugo, Jan Sradnick, Torsten Siepmann, Hansjörg Rothe, Tom H. Lindner, Torsten Tonn, Holger Schirutschke, Torsten Langer, Leona Anders, Kerstin Barnett, Friederike Kessel, Petra Müller, Moritz Anft, Robert Faulhaber-Walter, Hannah Kröger, Kirsten Anding-Rost, Jan Hüther, Thilo Pluntke, Anne Steglich, Frank Meistring, Kerstin Frank, Thomas Stehr, Claudia Karger, Anna Klimova, Joachim Beige, Ingolf Bast, Katja Escher, Jens Schewe, Timm H. Westhoff, Jörg Schwöbel, Arturo Blazquez-Navarro, Harald Seidel, Nina Babel, Frank Pistrosch, Heike Martin, Annegret Pietzonka, Ulrik Stervbo, Alexander Paliege, Simon Cerny, Florian Gembardt, and Julian Stumpf

Subjects
dialysis patients, Cellular immunity, medicine.medical_specialty, medicine.medical_treatment, Belatacept, mRNA-1273, humoral and cellular immune response, Immune system, medical personnel, Immunity, Internal medicine, Internal Medicine, medicine, guidelines, Seroconversion, Dialysis, clinical decision-making, business.industry, Health Policy, COVID-19, tozinameran, Vaccination, SARS-CoV-2 vaccination, Immunosuppressive drug, Oncology, epidemiology, BNT162b2, kidney transplant recipients, business, Research Paper, medicine.drug
Abstract

Background: Dialysis and kidney transplant patients are vulnerable populations for COVID-19 related disease and mortality. Methods: We conducted a prospective study exploring the eight week time course of specific cellular (interferon-I³ release assay and flow cytometry) or/and humoral immune responses (ELISA) to SARS-CoV-2 boost vaccination in more than 3100 participants including medical personnel, dialysis patients and kidney transplant recipients using mRNA vaccines BNT162b2 or mRNA-1273. Results: SARS-CoV-2-vaccination induced seroconversion efficacy in dialysis patients was similar to medical personnel (> 95%), but markedly impaired in kidney transplant recipients (42%). T-cellular immunity largely mimicked humoral results. Major risk factors of seroconversion failure were immunosuppressive drug number and type (belatacept, MMF-MPA, calcineurin-inhibitors) as well as vaccine type (BNT162b2 mRNA). Seroconversion rates induced by mRNA-1273 compared to BNT162b2 vaccine were 97% to 88% (p

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results